Deepening Presence in Southeast Asia ⋅ Strategic Collaboration Upgrade: World Expo of Packaging Industry-Southeast Asia 2026 Sets Sail Again in Jakarta

SHANGHAI, May 27, 2026 /PRNewswire/ -- From August 27 to 29, 2026, the 2nd World Expo of Packaging Industry-Southeast Asia, organized by RX, will be grandly held at the Jakarta International Expo (JIEXPO) in Indonesia.

Following its success in setting an industry benchmark in 2025, this year's exhibition will further deepen strategic cooperation. With World Expo of Packaging Industry-Southeast Asia at its core, the event will synergize with the Paper Chain Expo, Pack Plus and Bakery ASEAN. Spanning an exhibition area of over 22,000 square meters, it will create an international trade platform covering the entire industrial chain—from raw materials and equipment manufacturing to packaging processing and terminal applications—injecting strong momentum into the collaborative growth of Chinese and Southeast Asian industries.

As the largest economy in Southeast Asia, Indonesia is rapidly becoming a vital hub for regional manufacturing and foreign investment. In recent years, the rapid development of sectors such as e-commerce, food delivery, food and beverage, and pharmaceuticals has continuously driven the demand for paper packaging, eco-friendly packaging, and smart packaging. With a market reaching over 600 million people in ASEAN, Indonesia holds a significant position in the regional and international packaging industry.

World Expo of Packaging Industry-Southeast Asia 2026 will continue to cultivate the Indonesian market, actively responding to the China-ASEAN industrial cooperation strategy. By once again partnering with industry organizations such as the Asosiasi Kotak Karton Gelombang Indonesia (AKKGI) and leveraging resources from packaging, papermaking, and printing associations across multiple countries, its international influence continues to rise. Notably, AKKGI will organize all its member units to attend this year and will host its 2026 Annual Convention and Gala Dinner concurrently with the exhibition, facilitating face-to-face exchanges with 500 industry elites and brand buyers.

Furthermore, the overall scale of the 2026 exhibition has been further upgraded, with a total display area exceeding 22,000 square meters. Leveraging the platform advantages of World Expo of Packaging Industry-Southeast Asia, the exhibition will highlight core segments of the packaging industry chain. Through synergy with the Paper Chain Expo and Pack Plus, it will provide a one-stop platform for display and exchange, covering paper raw materials and chemical agents, packaging and printing equipment, eco-friendly materials, smart manufacturing solutions, and terminal applications.

In terms of business matching, World Expo of Packaging Industry-Southeast Asia will continue to leverage its professional expertise. Through precise buyer invitations, one-on-one business matching, and the TAP (Targeted Attendee Program), it will focus on connecting core procurement decision-makers, brand owners, and distributors within the region. It is expected to attract over 25,000 high-quality target buyers, providing robust support for exhibitors to efficiently expand into Southeast Asian and international markets.

Focusing on industry hotspots, World Expo of Packaging Industry-Southeast Asia 2026 will host several high-level industry forums and themed activities that delve into critical topics such as the sustainable and smart future of the Southeast Asian packaging industry, green manufacturing and sustainable packaging, halal food packaging standardization and green supply chain synergy, smart packaging and digital factories, packaging for food delivery and ready-to-eat meals, innovative materials and molding technologies, as well as new breakthroughs in the industrial application of pulp molding and food paper containers. These sessions are designed to provide a high-value platform for information exchange and business expansion for both exhibitors and professional visitors, further strengthening the professional leadership of World Expo of Packaging Industry-Southeast Asia within the regional packaging industry.

In 2026, World Expo of Packaging Industry-Southeast Asia represents more than just an upgrade in scale and content; it is a commitment to the continuous cultivation and collaborative construction of the Southeast Asian packaging industry ecosystem.

We look forward to reuniting with global industry colleagues from August 27 to 29 at the Jakarta International Expo (JIEXPO), Indonesia.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Deepening Presence in Southeast Asia ⋅ Strategic Collaboration Upgrade: World Expo of Packaging Industry-Southeast Asia 2026 Sets Sail Again in Jakarta

SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals.

The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in the detection of cancers within the scope of the assay, including breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial and head & neck cancers.

The FDA grants Breakthrough Device Designation to certain qualifying devices that have the potential to provide for more effective diagnosis of life-threatening or irreversibly debilitating diseases, such as cancer, than current options.

"Receiving FDA Breakthrough Device Designation for SPOT-MAS 10 is a defining milestone for Gene Solutions and reflects the potential of our multi-omic approach in cancer screening," said Dr. Nguyen Hoai Nghia, CEO & Co-founder of Gene Solutions. "This recognition strengthens our commitment to advancing accessible, evidence-based technologies that support earlier detection of cancers, especially for those where screening options remain limited — ultimately helping to improve patient outcomes worldwide."

SPOT-MAS has been developed through years of scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer early detection blood test in Asia to complete a large prospective cohort validation. Results from the K-DETEK study, published in BMC Medicine, evaluated SPOT-MAS in more than 9,000 asymptomatic participants and demonstrated strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.

SPOT-MAS has since been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and will be featured at ASCO Breakthrough 2026 in Singapore.

The SPOT-MAS platform is built on a multi-omic approach integrating genetics, epigenetics and fragmentomics, together with AI-driven analysis, prospective validation and real-world evidence. SPOT-MAS 10 is designed to complement — not replace — existing guideline-recommended screening programs while expanding screening opportunities for cancers that lack established screening pathways.

"Early cancer detection requires more than identifying a single molecular signal," said Dr. Le Son Tran, Principal Investigator of SPOT-MAS. "By integrating multiple layers of cell-free DNA information with machine learning, SPOT-MAS is designed to extract deeper biological signals from blood while maintaining the high specificity required for responsible screening."

For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans. Gene Solutions is targeting U.S. launch readiness in late 2026, supported by its ongoing U.S. laboratory and validation strategy.

Looking ahead, Gene Solutions will continue to collaborate with clinicians, regulators and global partners to generate evidence supporting the responsible implementation of SPOT-MAS 10 and its role in addressing unmet needs in cancer screening.

Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.

For more information, visit www.genesolutions.com.

Contact:
pr@genesolutions.com 

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test